LAUSR

https://ejgo.org Most women with advanced ovarian cancer develop recurrent disease after the firstline therapy, and chemotherapy remains the standard care of women with platinumsensitive recurrent ovarian cancer. The randomized studies (NCT00565851, NCT01166737, NCT01611766) comparing surgery with chemotherapy alone are on the way, and matured data will be reported in recent years [1,2]. The results of these studies may be different because of different clinical practice and different patient population. Different clinical practice came from years of experience and training background of secondary surgical cytoreduction in recurrent ovarian cancer from retrospective or prospective studies.